Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

Clinical trial NCT04802161 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04802161
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy Acute Myeloid Leukemia With Multilineage Dysplasia Chronic Myelomonocytic Leukemia Myelodysplastic Syndrome Myeloproliferative Neoplasm

Start date: 2022-08-24
Primary completion: 2024-11-21
Enrollment: 49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.